Unlocking the Power of Systems Thinking in Policymaking: A Path to Stronger Health Systems

By Staff Writer

July 3, 2023

Discover the untapped potential of systems thinking in shaping effective policies and practices published in a new article. 

Traditionally seen as too conceptual for policy relevance, systems thinking is now gaining traction in high-income countries, with governments embracing adaptive leadership and systemic evaluations. 

But what about low- and middle-income countries? Resource constraints often hinder the institutionalization of systems thinking, making it challenging to replicate successful examples.

To overcome this, the study proposes three key steps:

1️⃣ Theorise and clarify the terminology of applied systems thinking in health policy and systems research (HPSR). By utilising systems modeling and other tools, we can better understand the interactions between interventions and their contexts. 

2️⃣ Encourage greater government investment and institutional incentives to foster long-term collaboration and science-policy partnerships. This will enhance the capacities and practice of systems thinking in policymaking. 

3️⃣ Advocate for funding norms that enable systems thinking in LMICs. Pooling resources and fostering networked institutions can address complexity and adaptive approaches, leading to more impactful outcomes. 

 

To read the full article click on the link below. 

Reference url

Recent Posts

masitinib prostate cancer trial
        

Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study

🚀 What’s the next big thing in prostate cancer treatment?

The recent FDA and EMA authorizations for the masitinib prostate cancer trial could revolutionize care for metastatic castrate-resistant prostate cancer (mCRPC). This groundbreaking study employs a biomarker-driven strategy to optimize treatment outcomes for patients like never before!

Dive into the full article to explore the implications of this targeted therapy and how it may change the future of precision medicine in oncology.

#SyenzaNews #Oncology #PrecisionMedicine #HealthTech

BEBT-908 DLBCL treatment
        

BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhibitor in China

🚀 Are we on the brink of a revolution in DLBCL treatment?

The recent conditional approval of **BEBT-908** by China’s National Medical Products Administration is not just a milestone for oncology, but potentially a game-changer for adults battling relapsed or refractory diffuse large B-cell lymphoma. With its dual-target mechanism, this first-in-class therapy offers promising efficacy and a well-thought-out access strategy that could reshape treatment standards.

Dive into the full article to discover how BEBT-908 is setting new benchmarks in both clinical outcomes and healthcare affordability.

#SyenzaNews #oncology #pharmaceuticals #MarketAccess

AI Cost Implications
    

AI Clinician in Pediatric ICU: A Review and HEOR Perspective

🤖 What could AI Clinician support mean for pediatric ICU care?

A new collaboration between Imperial College London and CHOC is developing an AI system to guide treatment decisions in PICUs. This article reviews the initiative and examines its broader health system implications—offering a Health Economics and Outcomes Research (HEOR) perspective on how AI may shape efficiency, equity, and value in critical care.

Read on to explore how clinical innovation intersects with healthcare economics.

#SyenzaNews #AIinHealthcare #HEOR #PediatricCare #HealthInnovation #PICU

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.